Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists
US7332501B2 · kind B2 · utility
5Cited by
1References
50Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2006 |
| Grant date | Feb 19, 2008 |
| Priority date | — |
| Expiry date | Aug 2, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D491/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I:wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.